Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness

Peggy J. Pazzaglia, Robert M. Post, Terence A. Ketter, Ann M. Callahan, Lauren B. Marangell, Mark A Frye, Mark S. George, Tim A. Kimbrell, Gabriele S. Leverich, Gabriela Cora-Locatelli, David Luckenbaugh

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Of 30 patients with treatment-refractory affective illness, 10 showed a moderate to marked response to blind nimodipine monotherapy compared with placebo on the Clinical Global Impressions Scale. Fourteen inadequately responsive patients (3 unipolar [UP], 11 bipolar [BP]) were treated with the blind addition of carbamazepine. Carbamazepine augmentation of nimodipine converted four (29%) of the partial responders to more robust responders. Patients who showed an excellent response to the nimodipine-carbamazepine combination included individual patients with patterns of rapid cycling, ultradian cycling, UP recurrent brief depression, and one with BP type II depression. When verapamil was blindly substituted for nimodipine, two BP patients failed to maintain improvement but responded again to nimodiplne and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine. Mechanistic implications of the response to the dihydropyridine L-type CCB nimodipine alone and in combination with carbamazepine are discussed.

Original languageEnglish (US)
Pages (from-to)404-413
Number of pages10
JournalJournal of Clinical Psychopharmacology
Volume18
Issue number5
DOIs
StatePublished - Oct 1998
Externally publishedYes

Fingerprint

Nimodipine
Carbamazepine
L-Type Calcium Channels
Calcium Channel Blockers
Isradipine
Verapamil
Bipolar Disorder
Placebos
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. / Pazzaglia, Peggy J.; Post, Robert M.; Ketter, Terence A.; Callahan, Ann M.; Marangell, Lauren B.; Frye, Mark A; George, Mark S.; Kimbrell, Tim A.; Leverich, Gabriele S.; Cora-Locatelli, Gabriela; Luckenbaugh, David.

In: Journal of Clinical Psychopharmacology, Vol. 18, No. 5, 10.1998, p. 404-413.

Research output: Contribution to journalArticle

Pazzaglia, PJ, Post, RM, Ketter, TA, Callahan, AM, Marangell, LB, Frye, MA, George, MS, Kimbrell, TA, Leverich, GS, Cora-Locatelli, G & Luckenbaugh, D 1998, 'Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness', Journal of Clinical Psychopharmacology, vol. 18, no. 5, pp. 404-413. https://doi.org/10.1097/00004714-199810000-00009
Pazzaglia, Peggy J. ; Post, Robert M. ; Ketter, Terence A. ; Callahan, Ann M. ; Marangell, Lauren B. ; Frye, Mark A ; George, Mark S. ; Kimbrell, Tim A. ; Leverich, Gabriele S. ; Cora-Locatelli, Gabriela ; Luckenbaugh, David. / Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. In: Journal of Clinical Psychopharmacology. 1998 ; Vol. 18, No. 5. pp. 404-413.
@article{9616288181aa46c8939426bd993e54e9,
title = "Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness",
abstract = "Of 30 patients with treatment-refractory affective illness, 10 showed a moderate to marked response to blind nimodipine monotherapy compared with placebo on the Clinical Global Impressions Scale. Fourteen inadequately responsive patients (3 unipolar [UP], 11 bipolar [BP]) were treated with the blind addition of carbamazepine. Carbamazepine augmentation of nimodipine converted four (29{\%}) of the partial responders to more robust responders. Patients who showed an excellent response to the nimodipine-carbamazepine combination included individual patients with patterns of rapid cycling, ultradian cycling, UP recurrent brief depression, and one with BP type II depression. When verapamil was blindly substituted for nimodipine, two BP patients failed to maintain improvement but responded again to nimodiplne and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine. Mechanistic implications of the response to the dihydropyridine L-type CCB nimodipine alone and in combination with carbamazepine are discussed.",
author = "Pazzaglia, {Peggy J.} and Post, {Robert M.} and Ketter, {Terence A.} and Callahan, {Ann M.} and Marangell, {Lauren B.} and Frye, {Mark A} and George, {Mark S.} and Kimbrell, {Tim A.} and Leverich, {Gabriele S.} and Gabriela Cora-Locatelli and David Luckenbaugh",
year = "1998",
month = "10",
doi = "10.1097/00004714-199810000-00009",
language = "English (US)",
volume = "18",
pages = "404--413",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness

AU - Pazzaglia, Peggy J.

AU - Post, Robert M.

AU - Ketter, Terence A.

AU - Callahan, Ann M.

AU - Marangell, Lauren B.

AU - Frye, Mark A

AU - George, Mark S.

AU - Kimbrell, Tim A.

AU - Leverich, Gabriele S.

AU - Cora-Locatelli, Gabriela

AU - Luckenbaugh, David

PY - 1998/10

Y1 - 1998/10

N2 - Of 30 patients with treatment-refractory affective illness, 10 showed a moderate to marked response to blind nimodipine monotherapy compared with placebo on the Clinical Global Impressions Scale. Fourteen inadequately responsive patients (3 unipolar [UP], 11 bipolar [BP]) were treated with the blind addition of carbamazepine. Carbamazepine augmentation of nimodipine converted four (29%) of the partial responders to more robust responders. Patients who showed an excellent response to the nimodipine-carbamazepine combination included individual patients with patterns of rapid cycling, ultradian cycling, UP recurrent brief depression, and one with BP type II depression. When verapamil was blindly substituted for nimodipine, two BP patients failed to maintain improvement but responded again to nimodiplne and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine. Mechanistic implications of the response to the dihydropyridine L-type CCB nimodipine alone and in combination with carbamazepine are discussed.

AB - Of 30 patients with treatment-refractory affective illness, 10 showed a moderate to marked response to blind nimodipine monotherapy compared with placebo on the Clinical Global Impressions Scale. Fourteen inadequately responsive patients (3 unipolar [UP], 11 bipolar [BP]) were treated with the blind addition of carbamazepine. Carbamazepine augmentation of nimodipine converted four (29%) of the partial responders to more robust responders. Patients who showed an excellent response to the nimodipine-carbamazepine combination included individual patients with patterns of rapid cycling, ultradian cycling, UP recurrent brief depression, and one with BP type II depression. When verapamil was blindly substituted for nimodipine, two BP patients failed to maintain improvement but responded again to nimodiplne and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine. Mechanistic implications of the response to the dihydropyridine L-type CCB nimodipine alone and in combination with carbamazepine are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0031690746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031690746&partnerID=8YFLogxK

U2 - 10.1097/00004714-199810000-00009

DO - 10.1097/00004714-199810000-00009

M3 - Article

C2 - 9790159

AN - SCOPUS:0031690746

VL - 18

SP - 404

EP - 413

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -